$DWTX
Dogwood Therapeutics, Inc.

2022 Q1 Form 10-Q Financial Statement

#000155837022008661 Filed on May 13, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.192M $1.350M
YoY Change -11.7% 321.88%
% of Gross Profit
Research & Development $2.769M $1.707M
YoY Change 62.22% 5489.43%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.961M $3.057M
YoY Change 29.56% 699.22%
Operating Profit -$3.961M -$3.057M
YoY Change 29.56% 699.22%
Interest Expense $910.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $906.00 $1.400K
YoY Change -35.29% -101.67%
Pretax Income -$3.960M -$3.056M
YoY Change 29.59% 555.02%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$3.960M -$3.056M
YoY Change 29.59% 555.02%
Net Earnings / Revenue
Basic Earnings Per Share -$0.48 -$0.37
Diluted Earnings Per Share -$0.48 -$0.37
COMMON SHARES
Basic Shares Outstanding 8.330M 8.326M
Diluted Shares Outstanding 8.330M 8.326M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.35M $24.59M
YoY Change -53.83%
Cash & Equivalents $11.35M $24.59M
Short-Term Investments
Other Short-Term Assets $1.198M $3.690M
YoY Change -67.54%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $12.55M $28.27M
YoY Change -55.61%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $12.55M $28.27M
Total Long-Term Assets $0.00 $0.00
Total Assets $12.55M $28.27M
YoY Change -55.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $330.7K $614.7K
YoY Change -46.2%
Accrued Expenses $1.547M $552.6K
YoY Change 179.84%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.877M $1.167M
YoY Change 60.82%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.877M $1.167M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $1.877M $1.167M
YoY Change 60.82%
SHAREHOLDERS EQUITY
Retained Earnings -$47.89M -$31.00M
YoY Change 54.47%
Common Stock $833.00 $833.00
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.67M $27.11M
YoY Change
Total Liabilities & Shareholders Equity $12.55M $28.27M
YoY Change -55.61%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$3.960M -$3.056M
YoY Change 29.59% 555.02%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.656M -$5.112M
YoY Change -48.05% 1743.04%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -97.60K
YoY Change -100.0% -108.4%
NET CHANGE
Cash From Operating Activities -2.656M -5.112M
Cash From Investing Activities
Cash From Financing Activities 0.000 -97.60K
Net Change In Cash -2.656M -5.210M
YoY Change -49.02% -688.6%
FREE CASH FLOW
Cash From Operating Activities -$2.656M -$5.112M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8330390
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8326010
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001818844
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8330390
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8330390
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-39811
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Virios Therapeutics, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Alpharetta
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1706957
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1192112
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1350476
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
3961214
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-4314201
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
44 Milton Avenue
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 dei Trading Symbol
TradingSymbol
VIRI
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
58557510
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
58425604
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8330390
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47885681
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12549858
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11352167
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-43925373
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
10672662
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14008184
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30009
CY2022Q1 dei City Area Code
CityAreaCode
866
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
620-8655
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1197691
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1768503
CY2022Q1 us-gaap Assets Current
AssetsCurrent
12549858
CY2021Q4 us-gaap Assets Current
AssetsCurrent
15776687
CY2022Q1 us-gaap Assets
Assets
12549858
CY2021Q4 us-gaap Assets
Assets
15776687
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
330690
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
353863
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1546506
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
921760
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1877196
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1275623
CY2022Q1 us-gaap Liabilities
Liabilities
1877196
CY2021Q4 us-gaap Liabilities
Liabilities
1275623
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
43000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
43000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8330390
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8330390
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
833
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
833
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
3057433
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3961214
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
14501064
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15776687
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2769102
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3960308
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14008184
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3960308
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29795366
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
10672662
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11352167
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
14501064
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24585560
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3057433
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
906
CY2021Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1400
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
906
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1400
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3960308
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3056033
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3960308
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3056033
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8330390
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8326010
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
131906
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
29940889
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24825
CY2021Q1 viri Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
197562
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3056033
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
27107243
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-3960308
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-3056033
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
131906
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
24825
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-570812
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2011612
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-23173
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
530803
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
624746
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-221352
CY2021Q1 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
-378833
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2656017
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5112202
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
197562
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
295166
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-97604
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2656017
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-5209806
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3056033
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2656017
CY2022Q1 viri Prepaid Services
PrepaidServices
27995
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5112202
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47885681
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of these financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include estimated work performed but not yet billed by contract manufacturers, engineers and research organizations, the valuation of equity and stock-based related instruments, and the valuation allowance related to deferred taxes. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Actual results could differ from those estimates.</p>
CY2022Q1 us-gaap Prepaid Insurance
PrepaidInsurance
1010707
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1329385
CY2022Q1 viri Prepaid Clinical Research Costs
PrepaidClinicalResearchCosts
124915
CY2021Q4 viri Prepaid Clinical Research Costs
PrepaidClinicalResearchCosts
422591
CY2021Q4 viri Prepaid Services
PrepaidServices
15664
CY2022Q1 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
34074
CY2021Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
863
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1197691
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1768503
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
24100
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
12500
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7375
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
236851
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
532678
CY2022Q1 viri Accrued Interest On Preferred Members Interest
AccruedInterestOnPreferredMembersInterest
188085
CY2021Q4 viri Accrued Interest On Preferred Members Interest
AccruedInterestOnPreferredMembersInterest
188085
CY2022Q1 viri Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
1021220
CY2021Q4 viri Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
138522
CY2022Q1 viri Accrued Director Fees Current
AccruedDirectorFeesCurrent
46500
CY2021Q4 viri Accrued Director Fees Current
AccruedDirectorFeesCurrent
31000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
41350
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1546506
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
921760
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
43000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
172500
CY2022Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.50
CY2022Q1 viri Warrants Exercisable Percentage
WarrantsExercisablePercentage
1
CY2022Q1 viri Warrants And Rights Intrinsic Value
WarrantsAndRightsIntrinsicValue
0
CY2021Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
17956000
CY2022Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0

Files In Submission

Name View Source Status
0001558370-22-008661-index-headers.html Edgar Link pending
0001558370-22-008661-index.html Edgar Link pending
0001558370-22-008661.txt Edgar Link pending
0001558370-22-008661-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20220331.xsd Edgar Link pending
tmb-20220331x10q.htm Edgar Link pending
tmb-20220331x10q_htm.xml Edgar Link completed
tmb-20220331xex31d1.htm Edgar Link pending
tmb-20220331xex31d2.htm Edgar Link pending
tmb-20220331xex32d1.htm Edgar Link pending
tmb-20220331xex32d2.htm Edgar Link pending
tmb-20220331_cal.xml Edgar Link unprocessable
tmb-20220331_def.xml Edgar Link unprocessable
tmb-20220331_lab.xml Edgar Link unprocessable
tmb-20220331_pre.xml Edgar Link unprocessable